Trial site
Centre Hospitalier de Perigueux
Périgueux, 24019, FranceNot linked to an institution yet
- 15running trials
- 4closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 23 trials
- Phase 42 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Recruiting7 trials
- Active, not recruiting5 trials
- Completed4 trials
- Not yet recruiting3 trials
- Lead sponsor
- Intergroupe Francophone du Myelome3 trials
- Assistance Publique - Hôpitaux de Paris2 trials
- Poitiers University Hospital2 trials
- Canadian Cancer Trials Group1 trial
- Centre Hospitalier de PAU1 trial
- and 10 more
Running trials
Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
NCT07843498· Phase 3· Hoffmann-La Roche· Source
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source
Recruiting
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
2024-517325-43-00· Phase 2· Centre Hospitalier Universitaire De Nantes· Source
Recruiting
Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk
NCT06845423· Phase 4· University Hospital, Brest· Source
Contact: May-Lise BOUVET, MD
Recruiting
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
NCT06561854· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
2024-515362-13-00· Phase 2/3· Centre Hospitalier Regional Et Universitaire De Brest· Source
Active, not recruiting
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
NCT05753384· Phase 3· Poitiers University Hospital· Source
Recruiting
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
NCT05338190· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
NCT05181735· Phase 1/2· Groupe Francophone des Myelodysplasies· Source
Active, not recruiting
MInimal Residual Disease Adapted Strategy
NCT04934475· Phase 3· Intergroupe Francophone du Myelome· Source
Active, not recruiting
Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia
NCT04276155· Phase 4· Centre Hospitalier de PAU· Source
Active, not recruiting
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
NCT04751877· Phase 3· Poitiers University Hospital· Source
Recruiting
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617· Phase 2· ImmunoVaccine Technologies, Inc. (IMV Inc.)· Source
Contact: Aude Jouinot
Active, not recruiting
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· Phase 3· Epizyme, Inc.· Source
Active, not recruiting
Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.
NCT04144387· Intergroupe Francophone du Myelome· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error